Development of new treatment for refractory malignant diseases and investigation of new cell death mechanisms
Project/Area Number |
20591254
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | Kyoto University |
Principal Investigator |
ADACHI Souichi Kyoto University, 大学院・医学研究科, 教授 (10273450)
|
Co-Investigator(Renkei-kenkyūsha) |
WATANABE Ken-Ichirou 京都大学, 大学院・医学研究科, 講師 (20324634)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 難治性血液腫瘍疾患 / 細胞死 / アポトーシス / オートファジー / 転移抑制 / 予後因子解析 |
Research Abstract |
We reported autophagy in malignant rhabdoid cells induced by depsipeptide and found that AIF translocation from mitochondria to nuclei has been related with this autophagy. We also analysed resistant mechanism of depsipeptide from our depsipepside-resisitant cell lines and ERK pathway was activated in these resistant cells. We established mouse osteosarcoma cell line which is easily metastasize to lung and treated those mice by zoledronic acid and CPT11. CPT11 inhibited invasion of osteosarcoma cells and inhibited lung metastasis in vivo. We also reported that exon 5 of BAALC as a new poor prognostic factor and CEBPA mutations as good prognostic marker in child acute myelogenous leukemia (AML).
|
Report
(4 results)
Research Products
(46 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article]2009
Author(s)
足立壮一
-
Journal Title
小児白血病の治療 血液診療エキスパート Vol 1. 白血病(中外医学社)
Pages: 108-111
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-